Clinical Trial News and Research

RSS

Anti-EphA3 antibody has anti-tumour effects against solid cancers

An international team of scientists has shown that an antibody against the protein EphA3, found in the micro-environment of solid cancers, has anti-tumour effects.

16 Aug 2014

Enzyme therapy may prevent skeletal abnormalities associated with neurofibromatosis type-1

An enzyme therapy may prevent skeletal abnormalities associated with the genetic disorder neurofibromatosis type-1, Vanderbilt investigators have discovered.

15 Aug 2014

Modified C. novyi-NT bacterium produces precisely targeted anti-tumor response

A modified version of the Clostridium novyi (C. novyi-NT) bacterium can produce a strong and precisely targeted anti-tumor response in rats, dogs and now humans, according to a new report from Johns Hopkins Kimmel Cancer Center researchers.

14 Aug 2014

Clinical trial tests COXEN model in bladder cancer to find promising treatment

Imagine being able to match a cancer's genes to the best treatment. That's the promise of COXEN (CO eXpression ExtrapolatioN) - a computer program that looks at a panel of cancer genes in a patient's tumor to predict whether it will respond to chemotherapy.

14 Aug 2014

AEG-1 protein blocks effects of retinoic acid in leukemia and liver cancer

Retinoic acid is a form of vitamin A that is used to treat and help prevent the recurrence of a variety of cancers, but for some patients the drug is not effective.

14 Aug 2014

Healthy men participating in Prostate Cancer Prevention Trial are most likely to undergo biopsy

Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all steps of the clinical trial are most likely to undergo a biopsy, according to a study published in Cancer Epidemiology, Biomarkers and Prevention - a journal of the American Association for Cancer Research.

14 Aug 2014

MicroVAX begins phase I clinical trial for proprietary cancer vaccine platform

MicroVAX, LLC, a biotech company located in Manassas, Virginia announced today the commencement of a phase I clinical trial for its unique and proprietary vaccine platform that allows under the provisions of an FDA IND entry of patients with cancers of the, breast, prostate, colon, ovary and lung, that have relapsed after initial salvage therapy.

13 Aug 2014

Neovasc revenues increase 58% to $4,404,515 in Q2 2014

Neovasc Inc. ("Neovasc" or the "Company") today announced financial results for the three months ended March 31, 2014. All results are reported in Canadian dollars unless otherwise stated.

13 Aug 2014

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS).

13 Aug 2014

Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Rigel Pharmaceuticals, Inc. today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease.

13 Aug 2014

VolitionRx installs automated liquid handling system to increase rate of blood sample analysis

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announced it has installed a Tecan EVO200 automated liquid handling system in its Namur, Belgium laboratory.

13 Aug 2014

Experts open new clinic to evaluate heart disease patients for participation in stem cell studies

Regenerative medicine experts at the Cedars-Sinai Heart Institute have opened a new clinic to evaluate heart and vascular disease patients for participation in stem cell medical studies.

13 Aug 2014

Study shows castor bean oil reduces epileptic seizures related to Glut1 deficiency

Two years ago, the parents of Chloe Olivarez watched painfully as their daughter experienced epileptic seizures hundreds of times a day.

12 Aug 2014

ChromaDex reports 42% increase in Q2 2014 net sales

ChromaDex Corp., an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the financial results for the quarter ended June 28, 2014.

12 Aug 2014

Clinical trial to investigate safety of neural stem cell transplantation in patients with spinal cord injuries

Researchers at the University of California, San Diego School of Medicine have launched a clinical trial to investigate the safety of neural stem cell transplantation in patients with chronic spinal cord injuries.

12 Aug 2014

GenoSpace completes financing deal with Thomson Reuters

GenoSpace, a precision medicine software company that has developed a comprehensive suite of tools to enable the broad use of genomic data in research and clinical care, today announced that it completed a financing deal with Thomson Reuters, the world leader in providing intelligent information for businesses and professionals.

12 Aug 2014

Omeros reports net loss of $18 million for second quarter 2014

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results and highlights for the second quarter of 2014.

12 Aug 2014

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2014. Financial highlights for the second quarter include revenues of $18.4 million and a net loss of $16.3 million, or $0.13 per share.

12 Aug 2014

BioSpecifics Technologies total revenue for second quarter decreases by 19%

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the second quarter ended June 30, 2014 and provided a corporate update.

12 Aug 2014

$Sacral magnetic stimulation effective in refractory stress incontinence$

Sacral magnetic stimulation effective in refractory stress incontinence

Sacral magnetic stimulation may be an effective treatment for stress urinary incontinence in women whose symptoms are refractory to standard therapies, a clinical trial suggests.

11 Aug 2014

Clinical Trial News and Research

Anti-EphA3 antibody has anti-tumour effects against solid cancers

Enzyme therapy may prevent skeletal abnormalities associated with neurofibromatosis type-1

Modified C. novyi-NT bacterium produces precisely targeted anti-tumor response

Clinical trial tests COXEN model in bladder cancer to find promising treatment

AEG-1 protein blocks effects of retinoic acid in leukemia and liver cancer

Healthy men participating in Prostate Cancer Prevention Trial are most likely to undergo biopsy

MicroVAX begins phase I clinical trial for proprietary cancer vaccine platform

Neovasc revenues increase 58% to $4,404,515 in Q2 2014

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

VolitionRx installs automated liquid handling system to increase rate of blood sample analysis

Experts open new clinic to evaluate heart disease patients for participation in stem cell studies

Study shows castor bean oil reduces epileptic seizures related to Glut1 deficiency

ChromaDex reports 42% increase in Q2 2014 net sales

Clinical trial to investigate safety of neural stem cell transplantation in patients with spinal cord injuries

GenoSpace completes financing deal with Thomson Reuters

Omeros reports net loss of $18 million for second quarter 2014

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

BioSpecifics Technologies total revenue for second quarter decreases by 19%

Sacral magnetic stimulation effective in refractory stress incontinence

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer